FindTrial
Sign In

The retrospective study of the incidence of premalignant stage of plasma cell disorders in patients who performed monoclonal protein testing

The retrospective study of the incidence of premalignant stage of plasma cell disorders in patients who performed monoclonal protein testing

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20240419005
Enrollment
1000
Registered
2024-04-19
Start date
2024-05-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premalignant stage of plasma cell disorders in patients premalignant stage plasma cell disorders incidence monoclonal protein testing

Interventions

premalignant stage of plasma cell disorders in patients who performed monoclonal protein testing in 2011 - 2021
Screening
premalignant stage of plasma cell disorders

Sponsors

Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who tested monoclonal protein using one of three methods: serum protein electrophoresis, immunofixation, serum free light chain in 2011 - 2021 2. Patients must not have been diagnosed with multiple myeloma or AL amyloidosis according to the diagnostic criteria of International myeloma working group 2014

Exclusion criteria

Exclusion criteria: 1. insufficient data needed for analysis

Design outcomes

Primary

MeasureTime frame
Number of premalignant stage of plasma cell disorders patients at the end of year review from hospital medical record—

Secondary

MeasureTime frame
Percentage of premalignant stage of plasma cell disorders patients at the end of year calculate from primary outcome—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Faculty of Medicine Siriraj Hospital

chutima.kua@mahidol.ac.th0896790959

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026